Immune Netw.  2013 Feb;13(1):30-33. 10.4110/in.2013.13.1.30.

Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist

• Lee YR
• Lee YH
• Kim KH
• Im SA
• Lee CK

• KMID: 2150768
• DOI: http://doi.org/10.4110/in.2013.13.1.30

Abstract

Previously we showed that biodegradable nanoparticles containing poly-IC or CpG oligodeoxynucleotide (ODN) together with ovalbumin (OVA) were efficient at inducing MHC-restricted presentation of OVA peptides in dendritic cells. The CTL-inducing activities of the nanoparticles were examined in the present study. Nanoparticles containing poly-IC or CpG ODN together with OVA were prepared using biodegradable polymer poly(D,L-lactic acid-co-glycolic acid), and then were opsonized with mouse IgG. The nanoparticles were injected into the tail vein of mice, and 7 days later the OVA-specific CTL activities were measured using an in vivo CTL assay. Immunization of mice with the nanoparticles containing poly-IC or CpG ODN together with OVA elicited potent OVA-specific CTL activity compared to those containing OVA only. In accordance with these results, nanoparticles containing poly-IC or CpG ODN together with OVA exerted potent antitumor activity in mice that were subcutaneously implanted with EG7.OVA tumor cells. These results show that encapsulation of poly-IC or CpG ODN together with antigen in biodegradable nanoparticles is an effective approach for the induction of potent antigen-specific CTL responses in vivo.

Keyword

PLGA; Nanoparticle; Poly-IC; CpG; CTL; Antitumor activity

MeSH Terms

Animals
Dendritic Cells
Immunization
Immunoglobulin G
Lactic Acid
Mice
Nanoparticles
Ovalbumin
Ovum
Peptides
Polyglycolic Acid
Polymers
Veins
Immunoglobulin G
Lactic Acid
Ovalbumin
Peptides
Polyglycolic Acid
Polymers

Figure

• 

  Figure 1 The CTL inducing activities of the nanoparticles. The nanoparticles containing OVA only (NP [OVA]), both OVA and poly-IC (NP [OVA+I:C], or both OVA and CpG ODN (NP[OVA+CpG]) were injected intravenously into tail veins of mice. Seven days later, an in vivo CTL assay was performed in the mice using CFSE-labeled syngeneic target cells. (A) Representative histograms of the slpeen cells of individual mice were shown. The percentages of specific killing of OVA[257-264] peptide-pulsed target cells in the spleens (B) and lymph nodes (C) were graphically represented.

• 

  Figure 2 The antitumor activities of the nanoparticles. (A) Mice were immunized with the nanoparticles containing bovine serum albumin (BSA) only (NP[BSA]), OVA only (NP[OVA]), both OVA and poly-IC (NP[OVA+I:C], or both OVA and CpG ODN (NP[OVA+CpG]), intravenously into tail veins of the mice. Seven days later, the mice were subcutaneously implanted with EG7.OVA tumor cells (5×105/mouse). Two days later, the mice were again immunized with the same nanoparticles intravenously into tail veins of the mice. The tumor size was measured with a slide caliper and expressed as a tumor index, determined as the square root of (major axis×minor axis). (B) Mice were subcutaneously implanted with the tumor cells, and then mixtures of NP[OVA+I:C] and NP[OVA+CpG] were injected into the tumor mass on 10, 12 and 14 days after the tumor implantation.

Reference

1. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002. 188:51–64.

2. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994. 264:961–965.

3. Harding CV. Phagocytic processing of antigens for presentation by MHC molecules. Trends Cell Biol. 1995. 5:105–109.

4. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 1999. 398:77–80.

5. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001. 19:47–64.

6. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today. 1998. 19:368–373.

7. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006. 117:78–88.

8. Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, Han K, Kim K, Lee CK. Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide-co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res. 2007. 30:1440–1446.

9. Lee YR, Lee YH, Im SA, Yang IH, Ahn GW, Kim K, Lee CK. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. Arch Pharm Res. 2010. 33:1859–1866.

10. Schliehe C, Redaelli C, Engelhardt S, Fehlings M, Mueller M, van Rooijen N, Thiry M, Hildner K, Weller H, Groettrup M. CD8-dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol. 2011. 187:2112–2121.

11. Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly (d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci. 1998. 87:1421–1427.

12. Venkataprasad N, Coombes AG, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM. Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine. 1999. 17:1814–1819.

13. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han K, Kim K, Eo SK, Lee CK. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood. 2005. 105:3951–3955.

14. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003. 55:329–347.

15. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988. 54:777–785.

16. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003. 55:329–347.

17. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature. 1993. 361:359–362.

18. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004. 22:2406–2412.

19. Lee YH, Lee YR, Kim KH, Im SA, Song S, Lee MK, Kim Y, Hong JT, Kim K, Lee CK. Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells. Int Immunopharmacol. 2011. 11:985–991.

20. Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and characterization of antigen-loaded PLGA nanoparticles for efficient cross-priming of the antigen. Immune Netw. 2011. 11:163–168.